Michelle Nelken

Clinical Operations

Michelle Nelken has over 15 years experience in the pharmaceutical and biotechnology industry focusing on management of early and late phase clinical studies in multiple therapeutic areas, with a strong focus on rare diseases.  During her career, Ms. Nelken’s contribution has help lead to the approval of Genzyme’s Myozyme® for treatment of Pompe disease, Genzyme’s OSOM® Trichomonas Rapid Test, and most recently the Japanese approval of Strensiq® for Alexion Pharmaceuticals.